{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Is SAB Biotherapeutics, Inc. overvalued or undervalued?
As of May 9, 2025, SAB Biotherapeutics, Inc. is considered overvalued and has been downgraded to "does not qualify" due to negative financial ratios and a year-to-date return of -53.61%, significantly underperforming the S&P 500.
Is SAB Biotherapeutics, Inc. technically bullish or bearish?
As of April 25, 2025, the market trend is mildly bearish, influenced by daily moving averages and mixed signals from weekly indicators, suggesting indecision overall.
What does SAB Biotherapeutics, Inc. do?
SAB Biotherapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $5 million and a market cap of $16.54 million. Key metrics include a P/E ratio of NA, a dividend yield of 0.00%, and a return on equity of -183.22%.
How big is SAB Biotherapeutics, Inc.?
As of Jun 18, SAB Biotherapeutics, Inc. has a market capitalization of 16.54 million, with net sales of 0.37 million and a net profit of -34.28 million over the latest four quarters. The company reported shareholder's funds of 25.97 million and total assets of 46.06 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
